drugset / Trial / NCT01435902

A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise

NCT01435902

Phase 3 Withdrawn GlaxoSmithKline
RandomizedCrossoverDouble-blindTreatment

Summary

The primary objective of this study is to demonstrate that the combination of inhaled fluticasone furoate/vilanterol (100 mcg/25 mcg) once daily provides superior protection throughout the day against bronchoconstriction induced by exercise compared with fluticasone propionate 250 mcg twice daily in adolescent and adult subjects aged 12 to 50 diagnosed with persistent asthma.

Timeline

Start
2012-01
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluticasone Furoate Other / unclassified 100 ug Oral
Comparator Fluticasone propionate Other / unclassified 250 ug Oral
Comparator Vilanterol Other / unclassified 25 ug Oral

Indications